OTLC Stock Overview
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oncotelic Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.041 |
| 52 Week High | US$0.052 |
| 52 Week Low | US$0.01 |
| Beta | 0.062 |
| 1 Month Change | 3.29% |
| 3 Month Change | 5.70% |
| 1 Year Change | -7.27% |
| 3 Year Change | -86.40% |
| 5 Year Change | -80.57% |
| Change since IPO | -62.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| OTLC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | 0.4% | 1.0% |
| 1Y | -7.3% | 0.9% | 21.9% |
Return vs Industry: OTLC underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: OTLC underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| OTLC volatility | |
|---|---|
| OTLC Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OTLC has not had significant price volatility in the past 3 months.
Volatility Over Time: OTLC's weekly volatility has decreased from 22% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Vuong Trieu | www.oncotelic.com |
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company’s lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies.
Oncotelic Therapeutics, Inc. Fundamentals Summary
| OTLC fundamental statistics | |
|---|---|
| Market cap | US$16.31m |
| Earnings (TTM) | -US$7.90m |
| Revenue (TTM) | US$70.00k |
233.0x
P/S Ratio-2.1x
P/E RatioIs OTLC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTLC income statement (TTM) | |
|---|---|
| Revenue | US$70.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$70.00k |
| Other Expenses | US$7.97m |
| Earnings | -US$7.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.00% |
| Net Profit Margin | -11,290.13% |
| Debt/Equity Ratio | 108.3% |
How did OTLC perform over the long term?
See historical performance and comparison